8-K: Neuronetics Secures $10M, Reports Mixed Q2 Results

Neuronetics, Inc. announced its second quarter 2025 financial results, securing an additional $10 million in debt funding while adjusting its full-year financial outlook and delaying cash flow breakeven expectations.

Summary

• Total revenue for Q2 2025 reached $38.1 million, marking a 132% increase year-over-year and an 18% adjusted pro forma growth.
• Greenbrook clinic revenue hit a record $23.0 million in the quarter.
• Cash used in operations was reduced to $3.5 million, outperforming the guidance of under $5 million.
• The company secured an additional $10 million in funding from Perceptive Advisors LLC under its existing debt agreement in August 2025, with eligibility for another $5 million.
• The minimum liquidity balance requirement was lowered to $2 million through September 30, 2026, extending from the previous September 2025 deadline, after which it reverts to $5 million.
• Gross margin for Q2 2025 decreased to 46.6% from 74.0% in Q2 2024, primarily due to the inclusion of Greenbrook's clinic business.
• Operating expenses increased by 25% to $25.8 million, mainly driven by Greenbrook's general and administrative expenses.
• Net loss remained at $(9.8) million for Q2 2025, consistent with Q2 2024, but net loss per share improved to $(0.15) from $(0.33) due to increased shares outstanding.
• NeuroStar TMS demonstrated strong real-world efficacy in treating depression in adolescents and young adults, with nearly 70% experiencing clinically meaningful improvement.
• Steven Pfanstiel was appointed as the new Chief Financial Officer, effective July 15, 2025.

Sentiment

Score: 6

Explanation: The filing presents a mixed financial picture. While revenue growth is strong and cash burn was reduced, key profitability metrics (gross margin, operating expenses) and the timeline for achieving positive cash flow were revised negatively. The additional debt funding provides crucial liquidity, but the overall outlook suggests continued challenges in achieving sustained profitability despite growth initiatives.

Positives

• Achieved significant total revenue growth of 132% year-over-year to $38.1 million in Q2 2025.
• Reported 18% adjusted pro forma revenue growth for Q2 2025 compared to Q2 2024.
• Generated record Greenbrook clinic revenue of $23.0 million in the quarter, indicating successful integration.
• Reduced cash used in operations to $3.5 million, beating the guidance of under $5 million.
• Secured an additional $10 million in funding from Perceptive Advisors, enhancing liquidity.
• Extended the $2 million minimum liquidity requirement through September 30, 2026, providing financial flexibility.
• NeuroStar TMS showed strong real-world efficacy in adolescents and young adults, validating its FDA-cleared use in younger populations.
• Average selling price (ASP) per NeuroStar system was over $85,000, the highest in the past 5 years.

Negatives

• Gross margin decreased significantly to 46.6% in Q2 2025 from 74.0% in Q2 2024, primarily due to the Greenbrook clinic business inclusion.
• Operating expenses increased by 25% to $25.8 million, largely due to Greenbrook's general and administrative costs.
• U.S. NeuroStar Advanced Therapy System revenue decreased by 13% to $3.5 million, with 41 systems shipped, below the prior year quarter.
• U.S. treatment session revenue decreased by 8% to $10.8 million compared to Q2 2024.
• Full year 2025 gross margin guidance was lowered to 48%-50% from approximately 55%.
• Full year 2025 total operating expenses guidance was increased to $100 million-$105 million from $90 million-$98 million.
• Cash flow from operations is now expected to be negative $3 million to break-even in Q3 2025, a delay from the prior guidance of positive cash flow in Q3 2025.

Risks

• The effect of the Greenbrook transaction on business relationships, operating results, and business generally.
• Ability to execute the business strategy effectively.
• Ability to achieve or sustain profitable operations due to a history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System to generate revenues.
• The scale and efficacy of the salesforce.
• Ability to retain key talent.
• Availability of coverage and reimbursement from third-party payors for treatments using products.
• Physician and patient demand for treatments using products.
• Developments in respect of competing technologies and therapies for the indications that products treat.
• Potential for product defects.
• Revenue concentration among a small number of customers.
• Ability to obtain and maintain intellectual property protection for technology.
• Developments in clinical trials or regulatory review of the NeuroStar Advanced Therapy System for additional indications.
• Developments in regulation in the U.S. and other applicable jurisdictions.
• The terms of the credit facility.
• Ability to successfully roll-out the Better Me Provider Program on the planned timeline.
• Self-sustainability and existing cash balances.
• Ability to achieve cash flow breakeven in the fourth quarter of 2025 (revised from third quarter).

Future Outlook

For Q3 2025, total worldwide revenue is expected to be between $37.0 million and $39.0 million. The full year 2025 total worldwide revenue guidance is maintained at $149.0 million to $155.0 million. Full year 2025 gross margin is now expected to be between 48% and 50% (down from prior guidance of ~55%), reflecting product mix changes. Total operating expenses for full year 2025 are now projected to be between $100.0 million and $105.0 million (up from prior guidance of $90 million-$98 million). Cash flow from operations for Q3 2025 is anticipated to be in the range of negative $3 million to break-even, with positive cash flow from operations now expected in Q4 2025 (delayed from Q3 2025). Year-end 2025 total cash is expected to be between $25 million and $28 million, including the recent $10 million funding.

Management Comments

• "We're extremely pleased with our second quarter performance, which demonstrated solid revenue growth. Our Greenbrook integration continues to progress well, with record clinic revenue. We also reduced cash used in operations to just $3.5 million, better than our target." Keith Sullivan, President and CEO.
• "Our strong quarterly results are expected to help us achieve positive cash flow from operations in 2025 and I'm confident we're well-positioned to continue executing on our strategic priorities and drive sustainable growth for the remainder of 2025." Keith Sullivan, President and CEO.
• "We're also excited to welcome our new Chief Financial Officer, Steve Pfanstiel, who brings over two decades of experience driving growth and profitability at healthcare companies to the team." Keith Sullivan, President and CEO.

Industry Context

Neuronetics operates in the neurohealth and mental health technology sector, positioning itself as a leader in Transcranial Magnetic Stimulation (TMS) for depression and OCD. The company's acquisition of Greenbrook TMS Inc. signifies a strategic move towards vertical integration, combining a leading therapeutic platform with a large service provider network. This allows for broader access to treatments like NeuroStar Therapy and SPRAVATO, addressing the significant market of patients poorly served by traditional antidepressant medications. The positive real-world efficacy data for adolescents further expands the addressable market and reinforces NeuroStar's position as a non-drug, non-invasive treatment option in a field with limited safe alternatives for younger populations.

Comparison to Industry Standards

• Neuronetics positions itself as the 'Market Leader in Transcranial Magnetic Stimulation (TMS)' with the 'Largest direct sales and customer support team in the industry'.
• The NeuroStar TrakStar Clinical Database is cited as the 'world’s largest depression outcomes dataset'.
• The filing does not provide specific comparable companies, projects, or financial results for direct industry benchmarking beyond these qualitative statements of market leadership and scale.

Management Changes

Stakeholder Impact

• **Shareholders**: Mixed impact due to strong revenue growth and new funding, but also revised downward guidance for profitability and delayed cash flow breakeven. Share dilution from warrants issued to Perceptive.
• **Employees**: Potential impact from ongoing Greenbrook integration and efforts to optimize operations and achieve cost savings, balanced by augmentation in critical areas like claims collections.
• **Customers (Clinics)**: Benefits from continued support through the Better Me Provider Program, NeuroStar University, and centralized services, as well as expanded treatment options like SPRAVATO.
• **Patients**: Positive impact from expanded access to NeuroStar Therapy and SPRAVATO through the Greenbrook acquisition and positive real-world efficacy data for adolescents, offering more treatment options for mental health conditions.
• **Creditors (Perceptive Credit Holdings IV, LP)**: Strengthened position through additional warrants and continued debt servicing, with adjusted liquidity covenants.

Next Steps

• Continue Greenbrook integration and optimize the Spravato business mix.
• Leverage fixed infrastructure through continued growth to improve gross profit margin in the second half of 2025.
• Augment critical areas, including the claims collections team, to improve cash management.
• Fully assess and implement other synergies from the Greenbrook integration.
• Expand referral networks for Better Me Provider (BMP) Clinics and continue digital/DTC patient education.
• Expand SPRAVATO offering to over 80 treatment centers by the end of Fiscal 2025.
• Achieve positive cash flow from operations in the fourth quarter of 2025.

Key Dates

Recommendation

The filing presents a balanced view of progress and challenges. While Neuronetics demonstrates strong revenue growth, particularly from the Greenbrook acquisition, and has successfully reduced cash burn, the revised guidance for gross margin, operating expenses, and the delayed timeline for achieving positive cash flow indicate ongoing profitability hurdles. The additional $10 million in funding provides necessary liquidity, but the issuance of warrants to the lender represents some dilution. A seasoned investor would likely 'hold' to observe if the company can execute on its revised guidance, improve gross margins, and achieve sustainable positive cash flow in the coming quarters, as the long-term potential in the mental health market remains strong but short-term execution risks persist.

Keywords

NeuroStar, TMS, Transcranial Magnetic Stimulation, Depression Treatment, Mental Health, Medical Technology, Greenbrook, SEC Filing, Financial Results, Debt Financing, Q2 Earnings, Neuroscience, SPRAVATO